CSS
EDIT icon

Cubist Systematic Strategies’s Editas Medicine EDIT Stock Holding History

Cubist Systematic Strategies’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$994K Buy
286,482
+273,393
+2,089% +$763K ﹤0.01% 1954
2025
Q2 		$28.8K Buy
+13,089
New +$21.4K ﹤0.01% 2816
2025
Q1 		– Sell
-7,115
Closed -$9.04K – 3011
2024
Q4 		$9.04K Sell
7,115
-464,093
-98% -$1.18M ﹤0.01% 2864
2024
Q3 		$1.61M Buy
+471,208
New +$2.05M 0.01% 1547
2024
Q1 		– Sell
-212,170
Closed -$2.15M – 3862
2023
Q4 		$2.15M Buy
+212,170
New +$1.86M 0.01% 1454
2023
Q3 		– Sell
-54,497
Closed -$449K – 3487
2023
Q2 		$449K Sell
54,497
-364,591
-87% -$3.18M ﹤0.01% 2458
2023
Q1 		$3.04M Buy
+419,088
New +$3.73M 0.02% 1331
2022
Q4 		– Sell
-376,927
Closed -$4.61M – 4323
2022
Q3 		$4.61M Buy
376,927
+148,984
+65% +$2.32M 0.03% 1152
2022
Q2 		$2.7M Buy
227,943
+214,243
+1,564% +$2.87M 0.02% 1561
2022
Q1 		$261K Sell
13,700
-44,957
-77% -$836K ﹤0.01% 2916
2021
Q4 		$1.56M Buy
58,657
+52,183
+806% +$1.8M 0.01% 1589
2021
Q3 		$266K Sell
6,474
-4,151
-39% -$227K ﹤0.01% 2425
2021
Q2 		$602K Sell
10,625
-61,010
-85% -$2.25M 0.01% 1892
2021
Q1 		$3.01M Buy
71,635
+4,531
+7% +$258K 0.04% 754
2020
Q4 		$4.71M Buy
67,104
+35,854
+115% +$1.47M 0.06% 478
2020
Q3 		$877K Buy
31,250
+6,158
+25% +$201K 0.01% 1411
2020
Q2 		$742K Sell
25,092
-45,648
-65% -$1.19M 0.01% 1359
2020
Q1 		$1.4M Buy
70,740
+59,703
+541% +$1.51M 0.04% 641
2019
Q4 		$327K Buy
+11,037
New +$276K 0.01% 1805
2019
Q3 		– Sell
-48,326
Closed -$1.2M – 2267
2019
Q2 		$1.2M Buy
+48,326
New +$1.15M 0.02% 935
2019
Q1 		– Sell
-3,532
Closed -$80K – 2287
2018
Q4 		$80K Buy
3,532
+200
+6% +$5.44K ﹤0.01% 1799
2018
Q3 		$106K Buy
+3,332
New +$108K 0.01% 1595
2018
Q2 		– Sell
-10,631
Closed -$352K – 1851
2018
Q1 		$352K Buy
+10,631
New +$379K 0.02% 1039

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cubist Systematic Strategies's EDIT Position: Q3 2025 in Review

Cubist Systematic Strategies increased its Editas Medicine (EDIT) stake by 2,089% in Q3 2025, buying an estimated $763K and bringing the position to 286,482 shares worth $994K. The position accounts for ﹤0.01% of the portfolio, ranked #1954.

Cubist Systematic Strategies first reported a position in EDIT in Q1 2018 and has held it in 23 quarters since. The position peaked at $4.71M in Q4 2020. 193 funds tracked by Wall St. Rank hold EDIT as of Q3 2025.

  • Cubist Systematic Strategies held 286,482 shares of Editas Medicine worth $994K as of Q3 2025.
  • Cubist Systematic Strategies bought 273,393 Editas Medicine shares in Q3 2025, an estimated $763K.
  • Editas Medicine made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1954 holding.
  • Cubist Systematic Strategies first reported a position in Editas Medicine in Q1 2018 and has held it in 23 quarters since.
  • Cubist Systematic Strategies's Editas Medicine position peaked at $4.71M in Q4 2020.
  • 193 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.